Oncodesign S.A. is now Oncodesign Services S.A.
Following a general meeting of sharehoders* today, we announced the change of name to Oncodesign Services. This is the last step of a process initiated last July aiming at the separation of the R&D Biotech and Services activities of Oncodesign (see Press Release of the 1st July)
Oncodesign Services is a leading Contract Research Organization (CRO) specialized in drug discovery and preclinical services in oncology and immuno-inflammation, whose mission is to contribute to the discovery of innovative therapies against cancers and serious diseases with high medical needs.
In October 2022, the company was acquired by ERES IV, advised by Elyan Partners. Since then, Fabrice Viviani, who headed Business Unit Services of Oncodesign SA, has been appointed as Chairman and Chief Executive Officer of Oncodesign Services.
Fabrice comments: “It’s a pleasure and an exciting challenge to lead such a great and dymamic company that has developed over the last 25 years many technological innovations to support the discovery of drugs in oncology and other diseases areas . With my new executive team, we have the ambition to keep the momentum and further expand our capabilities and expertise we offer to our clients..”
From left to right : Cyril Berthet, Gilles Cadiou, Fabrice Viviani, Francis Bichat, Sébastien Simon
This is the opportunity to also present Oncodesign Services’ new leadership team, they will help support Fabrice Viviani and guide the company through its next phase of growth:
- Cyril Berthet: Chief Operating Officer
- Francis Bichat: Chief Business Officer
- Gilles Cadiou: Chief Financial Officer
- Sébastien Simon: Chief Human Resources Officer
Finally, all those changes include a refreshed website (www.oncodesign-services.com) and all our emails ending with @oncodesign-services.com.
We look forward to serving you with a better and more customized service!
*Following the success of the simplified tender offer initiated by Cancer Buster Bidco SAS (controlled by ERES IV) as well as the implementation of the squeeze-out targeting the shares of Oncodesign Services, Cancer Buster Bidco SAS (controlled by ERES IV) fully owns Oncodesign Services.